Tenpoint Therapeutics Names Carol Kearney as Chief Commercial Officer
Tenpoint Therapeutics Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company dedicated to pioneering treatments that rejuvenate vision in the aging eye, has announced the appointment of Carol Kearney as Chief Commercial Officer (CCO). In her new role, Kearney will lead Tenpoint’s commercial strategy, including preparations for the potential U.S. launch of BRIMOCHOL™ PF, an investigational, preservative-free, once-daily eye drop designed to address the loss of near vision, commonly associated with presbyopia.
Strengthening Tenpoint’s Commercial Leadership
Carol Kearney’s appointment marks a significant milestone in Tenpoint’s evolution from a clinical-stage biotech firm to a fully integrated commercial organization. With more than 20 years of leadership experience in the biopharmaceutical industry, Kearney has a proven track record of successfully driving commercialization efforts for both private and publicly traded biotechnology companies.
“The appointment of Carol as our first Chief Commercial Officer is an important step forward in Tenpoint’s growth,” said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics. “With her extensive experience in ophthalmology and her commercial leadership, I am confident in Carol’s ability to quickly scale up our commercial efforts and prepare for a successful launch of BRIMOCHOL™ PF. We look forward to building a world-class commercial team under her leadership.”
As CCO, Kearney will be responsible for formulating and executing Tenpoint’s go-to-market strategies, ensuring the successful commercialization of its innovative ophthalmic pipeline. Her immediate focus will be on BRIMOCHOL™ PF, a novel treatment targeting presbyopia, a condition that affects millions of aging individuals worldwide. Additionally, she will work closely with Tenpoint’s leadership team to expand the company’s global footprint, foster strategic partnerships, and drive brand awareness in the ophthalmic space.
Carol Kearney’s Vision for Tenpoint’s Future
“I’m excited to join Tenpoint at this important and pivotal time in the company’s growth and development,” said Kearney. “Tenpoint’s innovative approach to presbyopia, and commitment to developing a pipeline targeting the largest areas of unmet need for rejuvenating vision in the aging eye is unparalleled. I look forward to collaborating with this talented and expanding team as well as industry leaders to deliver solutions that will significantly improve the quality of life for people living with presbyopia and other ophthalmic conditions.”
Kearney’s vast expertise in commercialization, product launches, and strategic planning will be instrumental in Tenpoint’s ability to bring groundbreaking treatments to market. Her leadership will help ensure that BRIMOCHOL™ PF, and other promising pipeline candidates, reach the patients who need them most.
A Proven Leader in Biopharmaceutical Commercialization
Prior to joining Tenpoint, Kearney served as Senior Vice President, Strategy Consulting at Lumanity, Inc. (formerly Clarion Healthcare, Inc.), where she advised biopharmaceutical companies, business units, and brands on strategies to accelerate growth, overcome challenges, and achieve commercial success. During her tenure, she played a crucial role in helping clients scale their organizations and launch new products successfully.
Kearney also brings significant ophthalmology and optometry expertise, having previously worked in global marketing roles at Pfizer and Pharmacia. Additionally, she held sales and marketing positions at Bausch & Lomb and worked with a wide range of ophthalmic companies developing products for conditions affecting both the anterior and posterior segments of the eye. Her deep understanding of the ophthalmic industry, combined with her strategic vision, positions her well to lead Tenpoint’s commercial initiatives and drive long-term success.
BRIMOCHOL™ PF: A Novel Treatment for Presbyopia
Presbyopia, the gradual loss of near vision due to aging, affects nearly 1.8 billion people worldwide. It can significantly impact daily activities such as reading, using digital screens, and performing close-up tasks. BRIMOCHOL™ PF is an investigational, preservative-free, once-daily eye drop designed to enhance near vision without the need for reading glasses or invasive procedures.
With Kearney at the helm of Tenpoint’s commercial strategy, the company aims to position BRIMOCHOL™ PF as a leading solution for presbyopia management. Her expertise in launching ophthalmic products will be critical in securing regulatory approvals, educating healthcare professionals, and ensuring broad market access.
Tenpoint’s Commitment to Innovation in Ophthalmology
Beyond BRIMOCHOL™ PF, Tenpoint is actively developing a robust pipeline of ophthalmic treatments designed to rejuvenate vision in aging eyes. The company’s approach focuses on addressing the most significant unmet needs in ophthalmology by leveraging cutting-edge science and technology.
Under Kearney’s leadership, Tenpoint is poised to expand its commercial operations and solidify its presence in the ophthalmic market. By assembling a world-class team and implementing innovative marketing and sales strategies, the company aims to become a leader in vision restoration therapies.
